Timothy M. Caldwell

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Bryan D. Smith, Michael D. Kaufman, Wei-Ping Lu et al. · Cancer Cell · 2019 · 270 citations

Pdgfra Variants, Oncogenic Agent, Medicine +9

Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against <i>BRAF</i> or <i>RAS</i> Mutant Tumor Cells

James R. Henry, Michael D. Kaufman, Sheng-Bin Peng et al. · Journal of Medicinal Chemistry · 2015 · 84 citations · Full text

Kinase Inhibitors, Pharmaceutical Chemistry, Tumor Biology +20

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

Bryan D. Smith, Michael D. Kaufman, Cynthia B. Leary et al. · Molecular Cancer Therapeutics · 2015 · 75 citations

Switch Control Pocket, Glioma, Tumor Biology +16

Switching mode generation and optimal estimation with application to skid-steering

Timothy M. Caldwell, Todd D. Murphey · Automatica · 2010 · 67 citations

Motion Control, Trajectory Planning, Engineering +6

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages

Bryan D. Smith, Michael D. Kaufman, Scott Wise et al. · Molecular Cancer Therapeutics · 2021 · 65 citations · Full text